CoreWeave's stock slides as insider selling sparks investor concerns

CoreWeave's stock slid 9% to $93.54 on Tuesday due to significant insider selling by executives, including CEO Michael Intrator, and its largest shareholder, Magnetar Financial, following the August lockup expiration. Magnetar alone divested $94.4 million in shares and established a collar options position to hedge its remaining exposure. This sell-off, which has seen the stock nearly halve from its June peak and drop 38% since a disappointing Q2 earnings report, notably impacts the valuation of CoreWeave's all-stock acquisition of Core Scientific, reducing the per-share value for Core Scientific shareholders from an initial $19.72 to $11.53.

Analysis

CoreWeave's stock price experienced a significant 9% decline to $93.54, driven by a wave of insider selling following the expiration of its post-IPO lockup period. The selling was substantial, involving key executives and the company's largest shareholder, Magnetar Financial, which divested $94.4 million in shares on August 28 and an additional 1.47 million shares earlier that month. Notably, Magnetar also implemented a collar options strategy, purchasing puts at a $70 strike and selling calls at a $175 strike, effectively hedging its remaining position and signaling a defined valuation range until March 2026. This selling pressure exacerbates an existing downtrend, with the stock having fallen approximately 38% since a weaker-than-expected Q2 earnings report and now trading at roughly half its June peak of $187. The sustained depreciation has material consequences for its planned all-stock acquisition of Core Scientific, as the implied value for Core Scientific shareholders has plummeted from $19.72 to $11.53 per share, casting uncertainty on the deal's economics.

Key Decisions for Investors

• Investors should treat the heavy insider selling from top executives and the largest shareholder as a significant near-term bearish signal, especially as it compounds negative momentum from a recent disappointing earnings report.
• The sharp decline in CoreWeave's stock has materially devalued the all-stock offer for Core Scientific, and arbitrageurs and Core Scientific investors must re-evaluate the deal's viability and attractiveness at the new implied price of $11.53 per share.
• Note Magnetar's collar options strategy, which establishes a perceived price floor of $70 and a ceiling of $175; this provides a tangible, long-term valuation framework that could inform hedging strategies or define potential entry and exit points for positions in CoreWeave.